Malaysia at unexpected center of vaccine meetings that highlight regional focus
06 April 2015
Two gatherings in Kuala Lumpur, Malaysia this week, although held separately, came close, but not quite, to bringing together the twin issues of vaccines and the practice of halal by Muslims who comprise a third of Asia's population. Apparently, neither of the two primary gatherings had the concerns of the other on its agenda.
India likely to extend price caps to more HIV, TB meds: Reuters
03 April 2015
After stirring up protest by expanding its list of drugs subject to price caps late last year, India is considering adding more to the list. This time, health officials are likely to add more drugs that treat HIV and tuberculosis, Reuters reports.
Watch out, pharma. Fitch says the M&A party could come with a hangover
03 April 2015
Biopharma has been on a bona fide dealmaking binge. Trouble is, that binge is starting to get too expensive--and too risky. That's what Fitch Ratings says in a new report that cautions against fast-and-loose dealmaking.
VC heavyweights back a $150M NYC biotech fund with Lilly and Celgene in tow
03 April 2015
New York City's nascent biotech investment fund is ready to get rolling, recruiting some venture capital partners to join Eli Lilly ($LLY), Celgene ($CELG) and GE Ventures ($GE) with hopes of pouring $150 million into the local life sciences startup scene.
FDA issues final guidance on the evaluation and labeling of abuse-deterrent opioids
02 April 2015
The U.S. Food and Drug Administration today issued a final guidance to assist industry in developing opioid drug products with potentially abuse-deterrent properties.
Germany's Merck KGaA sees emerging markets as bigger earnings driver than Europe
02 April 2015
Germany's Merck KGaA now considers the world's emerging markets as a group, with China a major driver, to be a greater revenue-producer than Europe, unit CEO Bernd Reckmann said in an interview.
Busiest Day for Health-Care Deals Is Set to Spawn More: Real M&A
02 April 2015
It’s the busiest day for takeovers in the health-care industry. UnitedHealth Group Inc. struck Monday’s largest purchase -- $13.2 billion for drug-benefit manager Catamaran Corp. Teva Pharmaceutical Industries Ltd. made a $3.1 billion splash back into dealmaking with Auspex Pharmaceuticals Inc. Horizon Pharma Plc agreed to buy Hyperion Therapeutics Inc. for $866 million to treat lucrative rare diseases. And Fujifilm Holdings Corp. is acquiring Cellular Dynamics International Inc., a maker of human cells, for $239 million. All figures include net debt.
Japan pharma market on track for $80B mark by 2020, but obstacles seen
02 April 2015
Japan's pharmaceutical market is forecast to reach close to the $80 billion mark by 2020--up from $72.8 billion in 2013--but three big "ifs" could keep it from reaching that mark.
Online drug sale plans in China see furious smoke, no fire yet
01 April 2015
China drug regulators have provided no clue as to when they will allow online sales of prescription drugs, but the players who would be involved and those with a vested interest are positioning themselves to be ready. The clearance is expected sometime this year.
Message is clear: Europe is in trouble in terms of pharma growth, experts say
01 April 2015
The European pharma market isn’t likely to deliver much growth over the next five years as generic markets commoditize, IMS Health VP Graham Lewis warned participants at the DCAT (Drug, Chemical and Associated Technologies) conference.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Four cancer centers opened in Russia in 2023
26 April 2024
Russia and the UAE can simplify the drug registration process
26 April 2024
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024